sarclisa news - Search News

Sarclisa, multiple myeloma and European Medicines Agency

GlobalData on MSN · 21h

EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade, plus Revlimid, plus dexamethasone (VRd) for treating newly diagnosed multiple myeloma (MM).

Pharmabiz · 4h

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H

Business Insider · 1d

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ

MarketWatch · 1d

Sanofi: Sarclisa Recommended for EU Approval by CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top

Sanofi wins appeal in spat with NICE over Sarclisa

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Zacks.com on MSN1mon

Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma

Following this approval, Sarclisa is the first anti-CD38 therapy in combination with VRd for treating transplant-ineligible ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results